Archives
Tomivosertib Suppresses Ectopic Activity in Human DRG
2026-09-23
A study in cultured human dorsal root ganglion neurons found that the MNK inhibitor tomivosertib rapidly and reversibly reduced spontaneous electrical activity associated with radiculopathy. The results connect MNK target engagement with changes in neuronal excitability, supporting further investigation while stopping short of demonstrating clinical efficacy for neuropathic pain.
ATM Inhibition and Fenofibrate in HGSOC
2026-09-23
The reference study links elevated ATM activity with metabolic vulnerabilities in high-grade serous ovarian cancer and identifies fenofibrate as a promising combination partner for ATM suppression. Its findings support a research strategy that connects DNA repair biology, PPARα-associated metabolism, and therapy-induced senescence in homologous-recombination-proficient disease.
SU6656 Src Tyrosine Kinases Inhibitor Guide
2026-09-22
SU6656 provides a practical way to interrogate Src-dependent megakaryocyte maturation, platelet production, endothelial survival, and tumor-vessel responses. This guide separates findings from the hiPSC platelet reference study from proposed pilot conditions for platelet and radiotherapy experiments.
Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer
2026-09-22
Mei et al. show that hyperthermia can reduce BRCA2 protein in BRCA2-proficient ovarian carcinoma, weakening homologous recombination and enhancing sensitivity to the PARP inhibitor niraparib. The study provides a mechanistic rationale for using thermal treatment to extend PARP-based DNA damage repair inhibition beyond tumors with pre-existing BRCA2 defects.
NBC19: NLRP3 Inflammasome Workflows
2026-09-21
NBC19 is a nanomolar NLRP3 inflammasome inhibitor for dissecting IL-1β release after Nigericin or ATP stimulation. This guide translates its differentiated THP-1 performance into reproducible workflows and connects cytokine assays with the lactate–HMGB1 biology reported in sepsis research.
AZD1390 ATM Kinase Inhibitor Workflows
2026-09-21
Build mechanism-led assays for ATM inhibition, radiation response, and checkpoint control in glioma and lung cancer models. This guide combines validated AZD1390 use cases with exploratory G-quadruplex workflows inspired by REV1–DHX36 biology, while separating established evidence from optimization recommendations.
Bestatin Hydrochloride: From Enzyme to Translation
2026-09-20
Bestatin hydrochloride, also known as Ubenimex, is more than a broad exopeptidase inhibitor. This thought-leadership guide connects aminopeptidase biology with angiogenesis inhibition, peptide processing, cancer research, and translational study design.
REV1–DHX36 Control of G-Quadruplex Replication
2026-09-19
The 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. Its findings reposition REV1 as a coordinator of G-quadruplex tolerance and connect defective processing with elevated ATM/ATR signaling and sensitivity to G4-stabilizing stress.
Decitabine Workflows for Cancer Epigenetics
2026-09-18
Build reproducible Decitabine experiments around dose-separated DNA hypomethylation, tumor suppressor gene reactivation, and cytotoxicity controls. This workflow translates new HNF4A findings in Helicobacter pylori-associated gastric cancer into practical assays for hematopoietic malignancy research and solid tumor epigenetic studies.
Tolazoline Workflows for Receptor and Islet Studies
2026-09-18
Build more interpretable α2-adrenergic and β-cell assays with exposure-controlled Tolazoline workflows. The compound is especially useful when receptor antagonism, airway tone, and insulin secretion must be separated experimentally rather than treated as a single pharmacological endpoint.
METTL14, m6A, and Ulcerative Colitis Inflammation
2026-09-17
The reference study identifies METTL14-dependent m6A modification of the lncRNA DHRS4-AS1 as a protective regulatory mechanism in ulcerative colitis. Its cell and mouse experiments connect DHRS4-AS1 with the miR-206/A3AR axis, providing a mechanistic framework for interpreting RNA methylation in intestinal inflammation and for designing complementary methylation-focused studies.
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-09-17
This study identifies METTL14-mediated m6A modification of the lncRNA DHRS4-AS1 as a protective regulatory mechanism in ulcerative colitis. Using TNF-α-stimulated Caco-2 cells and a DSS-induced murine colitis model, the authors connect METTL14 loss with DHRS4-AS1 suppression, miR-206/A3AR dysregulation, NF-κB activation, and aggravated inflammatory injury.
Ribociclib succinate: Reliable CDK4/6 Assays
2026-09-16
A scenario-based guide to using Ribociclib succinate (SKU B1084) in cell proliferation, viability, and cytotoxicity workflows. It addresses vehicle control, pH-dependent solubility, dose-response design, interpretation, and practical product selection for reproducible cancer research.
FUS–PARP1 Phase Separation and PAR Structure
2026-09-16
The 2024 study shows that FUS assembly with PARylated PARP1 depends not only on cations and polyamines but also on the branching architecture of PAR. Its reconstituted biophysical framework helps explain how DNA damage-associated condensates may be regulated and identifies variables that should be controlled in related DNA repair assays.
BRCA2, PARP1 Retention, and RAD51 Protection
2026-09-15
The reference study identifies PARP1 retention on resected DNA as a direct threat to RAD51 filament stability and shows that full-length BRCA2 counteracts this effect during homologous recombination. By combining biochemical reconstitution, single-molecule FRET, strand-exchange assays, and cellular localization microscopy, the work provides a mechanistic explanation for the vulnerability of BRCA2-deficient cells to PARP inhibition.